Clinical trials: Dementia Disorders
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in Preclinical Alzheimer's Clinical Composite with semantic processing (PACC5)…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- FUTURE-US (NCT04951284)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
- Trial name
- NCT03671889
- Testing
- Blood Brain Barrier (BBB) Disruption
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- InSightec
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Diagnostic Imaging
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.
- Trial name
- NCT01009359
- Testing
- F-18 DPA-714 (BAY85-8102)
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Dementia Alzheimer's Type
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Primary Objective: To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on…
- Trial name
- NCT01266525
- Testing
- SAR110894, Donepezil
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 291 people
- Sponsor
- Sanofi
Alzheimer's Disease, Huntington's Disease
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation.
- Trial name
- NCT00990613
- Testing
- Dimebon IR, Dimebon Transdermal
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Alzheimer Disease, Healthy
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin.
- Trial name
- NCT04451408
- Testing
- LY3372993
- Where
- 13 sites in United States, Japan
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid (β-amyloid), a sticky protein in the brain…
- Trial name
- NCT00594568
- Testing
- LY450139
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 1,537 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo.
- Trial name
- NCT01193608
- Testing
- AAB-003 (PF-05236812)
- Where
- 29 sites in United States, South Korea
- Volunteers
- 88 people
- Sponsor
- Pfizer
Alzheimer Disease
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
- Trial name
- NCT00568776
- Testing
- ELND005
- Where
- 62 sites in United States, Canada
- Volunteers
- 353 people
- Sponsor
- OPKO Health, Inc.
Alzheimer's Disease
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
The primary goal of this study is to evaluate the effect of PF-04360365 on the clearance of ABETA from the CSF (cerebrospinal fluid) in patients with mild Alzheimer's disease and healthy volunteers.
- Trial name
- NCT01005862
- Testing
- PF-04360365
- Where
- 3 sites in United States, Sweden
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Alzheimer's disease is the most common form of dementia and is the fourth leading cause of death among people 65 years of age and older.
- Trial name
- NCT01466088
- Testing
- Donepezil, AZD3480
- Where
- 33 sites in United States, Czechia and 3 more
- Volunteers
- 386 people
- Sponsor
- Targacept Inc.
Lewy Body Disease, Parkinson Disease
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9…
- Trial name
- NCT04764669
- Testing
- E2027
- Where
- 14 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
To evaluate the effects of multiple dose regimens of CHF 5074 administered once per day up to 2 years on potential biomarkers of neurodegeneration in subjects with mild cognitive impairment.
- Trial name
- CT05 (NCT01723670)
- Testing
- CHF 5074 1x, CHF 5074 2x
- Sponsor
- CERESPIR
Alzheimer Disease
Drug-Drug Interaction Study With Rifampin
The purpose of the study is to determine if the concomitant administration of rifampin with BMS-708163 will affect the Pharmacokinetics of BMS-708163 and to assess safety and tolerability of co-administration BMS-708163 and…
- Trial name
- NCT01002079
- Testing
- BMS-708163, Rifampin
- Where
- India
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides
This is a Phase I, open label, randomized, 6-way crossover, pilot PK study
- Trial name
- NCT03635879
- Testing
- MCTprocal medical food, Milk/tricaprilin oil blend, AC-1207
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cerecin
Normal Pressure Hydrocephalus
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
To determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples…
- Trial name
- NCT01092546
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GE Healthcare
Alzheimer Disease, Dementia
Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Cognition Disorders
- Trial name
- SUVN-502 (NCT03564964)
- Testing
- SUVN-502
- Sponsor
- Suven Life Sciences Limited
Alzheimer's Disease
Multiple Dose Study of TRx0037
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TRx0037 after multiple doses in elderly volunteers.
- Trial name
- NCT01253499
- Testing
- TRx0037
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- TauRx Therapeutics Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.